Ocuphire Pharma, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
  • Product Pipeline
    • Overview
    • Nyxol
    • APX3330
    • APX2009
    • Posters and Publications
  • Clinical Trials
    • Overview
    • ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330 Recruiting Completed
    • MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Completed
    • MIRA-3 Completed
    • MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol Completed
    • LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol Completed
    • VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine Completed
  • Partnerships
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Ocuphire in the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • Ocuphire in the News

Rexahn Pharmaceuticals to Present at the Rodman & Renshaw 13th Annual Healthcare Conference

Sep 8, 2011

Rexahn Pharmaceuticals Announces US Patent Issued for CNS-based Treatment of Sexual Dysfunction

Sep 6, 2011

European Patent granted for Neurotherapeutic Compositions

Aug 8, 2011

Rexahn Pharmaceuticals Completes Patient Enrollment in Serdaxin Phase IIb Clinical Trial for Major Depressive Disorder

Jun 22, 2011

Rexahn Pharmaceuticals Reports Enrollment Progress on Phase IIb Clinical Trial of Serdaxin for Depression

May 5, 2011

Rexahn Pharmaceuticals to Present at Needham & Company's 10th Annual Healthcare Conference

Apr 4, 2011

Rexahn Closes $10 Million in Registered Direct Offering

Mar 31, 2011

Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-5902 at AACR 102nd Annual Meeting

Mar 30, 2011

Rexahn to Raise $10 Million in Registered Direct Offering

Mar 28, 2011

Rexahn Pharmaceuticals Enrolls 100 Patients in Serdaxin(R) Phase IIb Clinical Trial for Depression

Mar 23, 2011
    • 1...
    • 23
    • 24
    • 25
    • 26
    • 27
    • 28
    • 29
    • 30
    • 31
    • 32
    • ...38
    Ocuphire Pharma, Inc.
    © Ocuphire Pharma, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Terms of Use